ChromaDex Corporation is a ChromaDex Corp. is a science-based integrated nutraceutical company devoted to improving the way people age.
ChromaDex Corporation (CDXC) had a good day on the market for Wednesday December 23 as shares jumped 4.3% to close at $5.09. About 266,145 shares traded hands on 1,408 trades for the day, compared with an average daily volume of n/a shares out of a total float of 61.79 million. After opening the trading day at $4.97, shares of ChromaDex Corporation stayed within a range of $5.13 to $4.95.
With today’s gains, ChromaDex Corporation now has a market cap of $314.5 million. Shares of ChromaDex Corporation have been trading within a range of $6.00 and $2.50 over the last year, and it had a 50-day SMA of $n/a and a 200-day SMA of $n/a.
ChromaDex Corp. is a science-based integrated nutraceutical company devoted to improving the way people age. ChromaDex scientists partner with leading universities and research institutions worldwide to discover, develop and create solutions to deliver the full potential of NAD and its impact on human health. Its flagship ingredient, NIAGEN nicotinamide riboside, sold directly to consumers as TRU NIAGEN, is backed with clinical and scientific research, as well as extensive IP protection. TRU NIAGEN is helping the world AGE BETTER. ChromaDex maintains a website at www.chromadex.com to which ChromaDex regularly posts copies of its press releases as well as additional and financial information about the Company.
ChromaDex Corporation is based out of Los Angeles, CA and has some 110 employees. Its CEO is Robert N. Fried.